Sven Lingjaerde



Co-Founding Partner of Endeavour Vision SA. In 2007 contributed to the launch of Endeavour II, a EUR 103 million Fund dedicated to ICT, Biotech and Medtech and in 2016 contributed to the launch of Endeavour MedTech Growth Fund, a EUR 250m Fund where Sven currently leads the Digital Health practice. Co-Founding Partner of Vision Capital, a Trans-Atlantic venture capital firm established in 1996, investing in European technology companies seeking to enter the US market. Vision Capital advised programs for $175 million in three funds with offices in San Francisco and Geneva, Switzerland. Former Managing Director of Genevest Consulting Group SA, a Swiss venture capital firm founded in 1983. Genevest developed an outstanding track record of early to expansion stage investments in high tech and biotech ventures on both sides of the Atlantic. With over twenty eight years of Venture Capital experience, Sven has developed an extensive network on both sides of the Atlantic. This network of contacts was leveraged through the European Tech Tour Association, which he founded in 1998 and later merged with Europe Unlimited in 2013 to become one of the leading European community linking entrepreneur, investors and corporates. Has won several awards for contribution to the European technology entrepreneurial ecosystem. He was responsible for investments including Actelion (IPO SIX), Atlantech (acquired by Cisco), Avalon (acquired by Bookham, now Oclaro), Axovan (acquired by Actelion), Calera (acquired by Scansoft, now Nuance), Dolphin IC (secondary sale), Endoart (acquired by Allergan), Kuros (IPO SIX), Lysis (acquired by Kudelski), MathSoft (IPO NASDAQ), Molecular Partners (IPO SIX), Noise Cancellation Technologies (IPO NASDAQ), Oncoethix (acquired by Merck), Paion (IPO Xetra), Sandisk (IPO NASDAQ, then acquired by Western Digital), SCM Microsystems (IPO NASDAQ & Neuer Mark), Thommen (secondary sale), Trintech (IPO NASDAQ), Virata (IPO NASDAQ, then acquired by Conexant)


Role: Investor - Venture Capital (VC)


Personal Expertise

Product/Technology: ICT; Energy; Clean Technology; Environment









Endeavour Vision invests in exceptional medtech companies – those with big ideas that’ll disrupt the status quo to deliver big outcomes. Although we started building our medtech team in 2008, we decided to focus exclusively on medtech in 2013. We knew its long-term potential and the lack of existing funds dedicated to medtech entrepreneurs meant the sector was full of bright prospects. Our team is now made up of over 100 years of investment experience with a deep understanding of the medtech sector. Investment isn’t just about capital. It needs to create trust and add value. That’s why our success relies on teamwork and our hands-on approach. Our team is the perfect mix of investor expertise, entrepreneurial experience, and specialists in technology and life sciences. We help the innovators and entrepreneurs grow and develop into thriving businesses. The combination of these factors means Endeavour Vision is the best option for medtech companies looking for growth, and investors.


Organisation Type: Investor - Venture Capital (VC)


Organsiation Activity

Markets: Research and experimental development on natural sciences and engineering, Research and experimental development on biotechnology, Healthcare, Scientific research and development, Software, Business Products & Services, Healthcare Software

Product/Technology: Medtech, Digital health

Stage: Expansion/Growth

Geography: Europe, Switzerland, America